English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 113160/144130 (79%)
Visitors : 50736534      Online Users : 407
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    政大機構典藏 > 理學院 > 心理學系 > 期刊論文 >  Item 140.119/112323


    Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/112323


    Title: Review article: novel therapies for hepatitis B virus cure – advances and perspectives
    Authors: Lin, Chih Lin
    Kao, Jia Horng
    林志陵
    Contributors: 心理系
    Keywords: alpha interferon;antiretrovirus agent;arc 520;at 130;at 61;bay 41 4109;besifovir;ccc 0346;ccc 0975;CD8 antigen;CRISPR associated protein;dv 601;entecavir;gs 4774;hepatitis B(e) antigen;lymphotoxin beta receptor agonist;nvr 1221;organic anion transporter 1;organic anion transporter 3;peginterferon alpha;programmed death 1 ligand 1;tenofovir alafenamide;tenofovir disoproxil;tg 1050;toll like receptor;toll like receptor 7;transcription activator like effector nuclease;unclassified drug;unindexed drug;vesatolimod;zinc finger nuclease;adaptive immunity;chronic hepatitis B;clinical effectiveness;concentration response;CRISPR Cas system;disease control;drug safety;gene amplification;gene expression;gene silencing;genetic transcription;Hepatitis B virus;human;innate immunity;long term care;nonhuman;phase 1 clinical trial (topic);phase 2 clinical trial (topic);phase 3 clinical trial (topic);practice guideline;priority journal;remission;Review;RNA interference;seroconversion;treatment response;virus capsid;virus replication
    Date: 2016-08
    Issue Date: 2017-08-31 11:07:46 (UTC+8)
    Abstract: Background: Current anti-viral therapies, interferon and nucleos(t)ide analogues, have been proven to reduce the progression of chronic hepatitis B (CHB). However, covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) persists, resulting in viral relapse after the discontinuation of treatment. Aim: To discuss and review novel therapies for chronic hepatitis B infection. Methods: Recent published studies which searched from PubMed were comprehensive reviewed. The key words include chronic hepatitis B, hepatitis B virus cure, covalently closed circular DNA, direct acting anti-virals and host targeting agents. Results: Several novel agents through viral and host targets approaches are under investigations towards functional cure of HBV. On the one hand, direct acting anti-virals targeting virus itself, such as HBV new polymerase inhibitor, entry inhibitor, engineered site-specific nucleases and RNA interference, could inhibit amplification of cccDNA as well as intrahepatic HBV infection and eliminate or silence cccDNA transcription. Inhibitors of HBV nucleocapsid assembly suppress capsid formation and prevent synthesis of HBV DNA. On the other hand, host targeting agents (HTA) include lymphotoxin-β receptor agonist, toll-like receptor agonist, immune checkpoint inhibitors and adenovirus-based therapeutic vaccine. Through enhancing innate and adaptive immune responses, these agents could induce noncytolytic destruction of cccDNA or attack HBV-infected hepatocytes. Conclusion: With these promising approaches, we hope to reach global hepatitis B virus control in the middle of this century.
    Relation: Alimentary Pharmacology and Therapeutics, 44(3), 213-222
    Data Type: article
    DOI 連結: http://dx.doi.org/10.1111/apt.13694
    DOI: 10.1111/apt.13694
    Appears in Collections:[心理學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    222.pdf359KbAdobe PDF2375View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback